Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14423625 | 0.90 | ECE1 (0.56) | PPARGPPARAGPR34LPAR1LPAR3 | |
| SCHEMBL4924172 | 0.87 | PPARG (0.56) | PPARGPPARAGPR34FFAR1FFAR4 | |
| SCHEMBL1177696 | 0.87 | ALDH1A1 (0.62) | KMT2AMMEACEALDH1A1HTT | |
| SCHEMBL12714246 | 0.86 | FFAR1 (0.63) | PPARGPPARAGPR34LPAR1LPAR3 | |
| SCHEMBL17931616 | 0.84 | NPC1 (0.58) | PPARGPPARAFFAR1FFAR4MME | |
| SCHEMBL9484576 | 0.84 | CTRB1 (0.64) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL7301416 | 0.84 | CTRB1 (0.64) | PPARGPPARAFFAR1FFAR4LTA4H | |
| SCHEMBL8246771 | 0.81 | ACACB (0.50) | LPAR1LPAR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL4774975 | 0.80 | LDHA (0.50) | KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL16766937 | 0.80 | LDHA (0.50) | KMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20080267888-A1 | Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-10-30 | — | — | US | disclosed |
| US-20080267888-A1 | Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-10-30 | — | — | US | disclosed |
| WO-2007042878-A1 | NOVEL HETEROCYCLIC ANALOGS OF BIPHENYL ETHERS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006126074-A2 | HETEROCYCLIC DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267888-A1 | Heterocyclic Derivatives | CYP11B2, MAPT, UGT1A1 | PPARG 2859/4885PPARA 4264/4885GPR34 1366/4885 |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | UGT2B7, CYP4B1, CYP1B1 | PPARG 90/4885PPARA 238/4885GPR34 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.